FIELD: pharmaceuticals.
SUBSTANCE: invention refers to pharmacy and concerns an aqueous pharmaceutical composition of LHRH analogue for sustained release for at least 2 weeks. Composition contains as an active ingredient an LHRH analogue, selected from triptorelin, deslorelin, nafarelin, gistrellin, buserelin, goserelin, gonadorelin and leuprorelin, or any pharmaceutically acceptable salts thereof; salt and water. Active ingredient or any of its pharmaceutically acceptable salts, salt and water is at least 95 % by weight with respect to the total weight of the composition, and the LHRH analogue is present in a concentration varying from 1 to 30 % by weight with respect to the total weight of the composition, and said composition does not contain any non-water-soluble, biodegradable and / or biocompatible (co)polymers.
EFFECT: invention provides preparing a pharmaceutical composition of said LHRH analogs for sustained release of the active ingredient.
15 cl, 1 dwg, 4 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HIGH STABILITY PHARMACEUTICAL COMPOSITIONS | 2007 |
|
RU2427383C2 |
| LIPID PRECONCENTRATE OF SUSTAINED RELEASE CATIONIC PHARMACOLOGICALLY ACTIVE SUBSTANCE AND PHARMACEUTICAL COMPOSITION CONTAINING IT | 2013 |
|
RU2649810C2 |
| GnRH ANALOGUE-CONTAINING COMPOSITIONS WITH DELAYED RELEASE | 2010 |
|
RU2549490C2 |
| PHARMACEUTICAL COMPOSITIONS WITH A SELECTED DURATION OF RELEASE | 2017 |
|
RU2756514C1 |
| PALMITIC ACID CONJUGATED PROLONGED GNRH DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING IT | 2018 |
|
RU2746566C2 |
| COMBINATION CONTAINING N-(3-METHOXY-5-METHYLPYRAZINE-2-YL)-2-(4-[1,3,4-OXADIAZOL-2-YL]PHENYL)PURIDINE-3-SULPHONAMIDE AND LHRH-ANALOGUE AND/OR BIPHOSPHONATE | 2004 |
|
RU2398588C2 |
| GnRH DERIVATIVES OF PROLONGED ACTION, CONJUGATED WITH FATTY ACID AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | 2019 |
|
RU2785717C2 |
| LIPID PRECONCENTRATE OF GNRH ANALOGUES WITH DELAYED RELEASE, AND PHARMACEUTICAL COMPOSITION CONTAINING IT | 2013 |
|
RU2646487C2 |
| STABLE NONAQUEOUS SINGLE-PHASE GELS AND COMPOSITIONS ON THEIR BASIS FOR DELIVERY FROM IMPLANTED DEVICE | 2003 |
|
RU2342118C2 |
| PHARMACEUTICAL COMPOSITION WITH PROLONGED RELEASE OF DODECAPEPTIDE INGRAMON | 2022 |
|
RU2793124C1 |
